In a study in mice, Dr. Joshua Rabinowitz has found that a Keto diet enhances the effectiveness of chemotherapy.
Lola Rahib and Patrick van der Valk explain how Cancer Commons and xCures are using real-world data to improve care for future patients.
Dr. Kenneth Yu is testing a blood-based assay that looks at which types of chemotherapies will work best for each pancreatic cancer patient.
Dr. Andrea Califano leads a precision oncology clinical trial of the OncoTreat platform, which looks at proteins to determine treatment.
Dr. Noelle LoConte discusses a clinical trial for cancer patients, including pancreatic cancer patients, that have an NRG1 gene fusion.
Drs. Andrew Aguirre and David Ting are teasing out the differences between pancreatic cancer subtypes, to get treatments that work better.
Dr. Jennifer Knox is leading the NeoPancONE trial for a biomarker that indicates which patients will respond better to certain chemotherapy before surgery.
Dr. Andrea Califano is using systems biology and cell regulators to find new targets in the search for ways to stop pancreatic cancer cells.
Dr. David Chang explains the Precision Panc initiative, a program through the UK’s NHS that helps pancreatic cancer patients find treatments.
Dr. Kentaro Sudo explores the possible causes for different responses to drugs among ethnic groups, pointing to the need for clinical diversity in trials.
Dr. Vinod Balachandran looks at the immune system of exceptional responders–patients who respond extremely well to chemotherapy–for treatment clues.
Dr. Ben George and colleagues at the Medical College of Wisconsin are using molecular profiling to determine the best chemotherapy for a patient’s pancreatic cancer.